

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2022	1	Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, Andrew Martin, Anthony Jaworski, Sonia Yip, Do-Youn Oh, Markus Moehler, Li-Tzong Chen, Tanios S. Bekaii-Saab, John Simes, David Goldstein. INTEGRATE IIb: A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC). ASCO GI Cancers Symposium; 20-22 January 2022; San Francisco & Online.	INTEGRATE IIb
2021	2	Tebbutt N, Burge M, Underhill C, Farrell M, Xie S, Nagrial A, Pavlakis N, Strickland A, Chong G, Tie J, Wong R, Price T, The AGITG MODULATE Study: Randomised phase II study testing manipulation of the tumour micro environment(TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). ESMO 2021	MODULATE
2021	3	Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Yip S, Oh D, Moehler M, Chen L, Bekaii-Saab T, Simes J, INTEGRATE II: A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) An international study led by the Australasian Gastrointestinal Trials Group (AGITG). ESMO 2021	INTEGRATE IIb
2021	4	Gormly K, Espinoza D, Hague W, Jeffrey M, Price T, Karapetis C, Arendse M, Armstrong J, Childs J, Frizelle F, Ngan S, Stevenson A, Mitchell J, York S, Jameson M, Ackland S, SPAR: Randomised Phase II study of Chemoradiation with or without Simvastatin as Preoperative Treatment for Rectal cancer (an AGITG trial), MOGA 2021.	SPAR
2021	5	Oar A, Kneebone A, Lee M, Goldstein D, Sjoquist KM, Le H., et al. Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high risk and locally advanced pancreatic cancer. ASCO 2021.	MASTERPLAN
2020	6	Day D, Chia JWK, Foo EMJ, Ali R, Toh HC, Segelov E, on behalf of the ASCOLT Investigators. Operational challenges of engaging the Asian Pacific (APAC) region in an academic oncology clinical trial. ESMO 2020.	ASCOLT
2020	7	Mercieca-Bebber R, Barnes EH, Wilson K, Samoon Z, Walpole E, Mai T, Ackland S, Burge M, Dickie G, Watson D, Leung J, Wang T, Bohmer R, Cameron D, Simes J, GebSKI V, Smithers M, Thomas J, Zalberg J, Barbour A, Patient-reported outcome (PRO) results from AGITG DOCTOR: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma, ESMO Virtual Congress 2020; 19-21 September 2020.	DOCTOR
2020	8	Ngan S, Capp A, Hartoepanu C, Dickie G, Sridharan S, Last A, Lee M, Du Plessis R, Tee H, Jameson M, Ackland S. SPAR: A randomized, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer. An AGITG clinical trial. Trans-Tasman Radiation Oncology Group (TROG), March 2020.	SPAR
2020	9	Pavlakis N, Ransom D, Wyld D, Sjoquist KM, Asher R, GebSKI V, Wilson K, Kiberu AD, Burge ME, Macdonald W, Roach P, Pattison DA, Butler P, Price TJ, Michael M, Lawrence BJ, Bailey DL, Leyden S, Zalberg JR, Turner H, Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide (CAPTEM): First results for pancreas and updated midgut neuroendocrine tumours (pNETS, mNETS). ASCO Annual Meeting; 1-4 June 2020; Chicago.	CONTROL NETS
2020	10	Pavlakis N et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II studies of Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) or CAPTEM alone for neuroendocrine tumours (NETs (Nuclear Medicine – Imaging and Therapy (PRRT)). European Neuroendocrine Tumour Meeting (ENETS), March 2020, Barcelona.	CONTROL NETS
2020	11	Burge M, Steer C, Sjoquist K, Chantrill L, Karapetis C, Nott L, Espinoza D, Oostendorp M, Yip S, Cuff J, Tebbutt N, MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. An Australasian Gastro-Intestinal Trials Group (AGITG) trial. ASCO GI Cancers Symposium; 23-25 January 2020; San Francisco.	MONARCC
2020	12	Pavlakis N, Ransom DT, Wyld D, Sjoquist K, Asher R, GebSKI V, Wilson K, Ddembe Kiberu A, Burge ME, Macdonald W, Roach P, Pattison DA, Butler P, Price TJ, Michael M, Lawrence BJ, Bailey DL, Leyden JC, Zalberg JR, Turner JH, First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs). ASCO GI Cancers Symposium; 23-25 January 2020; San Francisco.	CONTROL NETS
2019	13	Michael M, Lordick F, Smithers B, Zalberg J, Simes J, Findlay M, GebSKI V, O'Connell R, Miller D, Aiken C, York S, Wong R, Haustermans K, Swallow C, Darling G, Strickland A, Lee M, Ringash J, Thomas M, Leong T. TOPGEAR - a phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer: Comparison fo FLOT versus ECX/F. International Gastric Cancer Congress (IGCC) 2019, May 2019; Prague, Czech.	TOPGEAR
2019	14	Chua Y, Pavlakis N, Sjoquist K, Martin A, Tsobanis E, Yip S, Bang Y, Alcindor T, O'Callaghan C, Bekaii-Saab T, Grothey A, Chen L, Simes J, Zalberg J, Goldstein D, Komatsu Y, Machida N, Esaki T, Hara H, Shitara K, INTERGRATE II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer, Japanese Society of Medical Oncology (JSMO) 17-19 July 2019, Japan.	INTEGRATE II
2019	15	Yip D, Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). ASCO Annual Meeting; 1-4 June 2019; Chicago.	ALT-GIST
2019	16	Leong T, Pre/Peri- vs Post-operative radiation strategies for localised Gastric Cancer. Presented at the International Gastric Cancer Congress (IGCC) 2019, May 2019; Prague.	TOPGEAR
2019	17	Leong T, Perioperative Therapies for Gastric Cancer: Neoadjuvant Strategies and Indications. Presented at ASCO GI Cancers Symposium 2019 (American Society of Clinical Oncology), January 2019, San Francisco.	TOPGEAR
2018	18	Leong T, Multidisciplinary approach to resectable gastric cancer. Is there a role for radiotherapy? ESMO Asia 2018 ; 23-25 November 2018; Singapore.	TOPGEAR
2018	19	Rao S, Sclafani F, Eng C, Grønlie Guren M, Adams RA, Benson A, Sebag-Montefiore D, Segelov E, Bryant A, Peckitt A, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, Bridgewater J, Falk S, Glynne-Jones R, Arnold D, Cunningham D. InteAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDD) plus 5-fluorouracil (5-FU) vs capecitabine (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naive disease - An International Rare Cancers Initiative (IRCI trial). ESMO 19-23 October 2018; Munich.	InterAACT

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2018	20	Schmoll H-J, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne J-F, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig C, Zalcborg JR, Tebbutt NC, Mauer ME, Marreaud S, Lutz MP, Cutsem EV. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. ASCO Annual Meeting; 1-5 June 2018; Chicago.	PETACC 6
2018	21	Barbour A, Walpole ET, Mai GT, Barnes E, Watson DI, Ackland SP, Martin J, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk G, GebSKI V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcborg JR, Simes J, Smithers M. Progression-free survival and recurrence results for AGITG DOCTOR. Pre-operative cisplatin, 5-fluorouracil (5-FU) & docetaxel +/-radiotherapy after poor early response to cisplatin & 5-FU for resectable oesophageal adenocarcinoma. ESMO 19-23 October 2018; Munich.	DOCTOR
2018	22	Chantrill LA, Lipton LR, Hofman M, GebSKI V, Gill A, Markman B, Yip S, Karapetis CS, Pavlakis N, Wong SF, Ransom DT, Sjoquist KM, Nagrial A, Michael M, Rayani U, Oostendorp M, Simes J, Khasraw M. AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas. ASCO GI Cancers Symposium; 18-20 January 2018; San Francisco.	NABNEC
2018	23	Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Segelov E, Paul J, Haydon A, Iveson T, Stockler M. AGITG SCOT: Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? ASCO Annual Meeting; 1-5 June 2018; Chicago.	SCOT
2018	24	Saunders MP, Paul J, Crosby J, Brown G, Iveson T, Kerr R, Harkin A, Allan K, McQueen J, Pearson SR, Cassidy J, Medley LC, Raouf S, Harrison M, Brewster A, C. R, Ellis R, Thomas AL, Churn M, Maka N. SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. ASCO GI Cancers Symposium; 18-20 January 2018; San Francisco.	SCOT
2018	25	Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan C, Jonker D, J., Tu D, Chen E, Morgen E, Price TJ, Shapiro JD, Siu LL, Owzar K, Ratain MJ, Kubo M, Dubrovic A, Xu W, Mushiroda T, Liu G. The association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis. ASCO GI Cancers Symposium; 18-20 January 2018; San Francisco.	CO.20
2018	26	Townsend AR, Asher R, Price TJ, Lee CK, Dorward H, GebSKI V, Tomita Y, Tebbutt NC, Hardingham J. Single nucleotide polymorphisms in COL4A2, PPP1R17, and ARHGAP44 and prognostic value in metastatic colorectal cancer. ASCO GI Cancers Symposium; 18-20 January 2018; San Francisco.	MAX
2017	27	Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the idea analysis, ESMO; 8-12 September 2017; Madrid.	IDEA
2017	28	Burzykowski T, Coart E, Saad ED, Sargent D, Zalcborg J, Shi Q, Sommeijer DW, Buyse ME. Tumor-size-based endpoints as surrogates for overall survival in the ARCAD advanced colorectal cancer database. ASCO GI Cancers Symposium; 19-21 January 2017; San Francisco.	ARCAD
2017	29	Casali PG, Le Cesne A, Poveda A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Gelderblom H, Penel N, Kopp HG, Goldstein D, Martin Broto J, Gronchi A, Wardelmann E, Marreaud S, Zalcborg J, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. ESMO; 8-12 September 2017; Madrid.	EORTC 62024
2017	30	Chantrill LA, Nagrial A, Johns A, McKay S, Gill AJ, Pavlakis N, Grimison PS, Asghari G, Waddell N, Chou A, Chin VT, Sebastian LT, Verghis J, Yip S, Sjoquist KM, Simes J, Biankin A. Clinical utilization of targetable molecular results in pancreatic cancer: longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. ASCO GI Cancers Symposium; 19- 21 January 2017; San Francisco.	IMPACT
2017	31	Itchins M, Arena S, Rabindran J, Christopher N, Kim S, Gibbs E, Gill AJ, Maher R, Schembri G, Bailey E, Mittal A, S. B, Wong M, Hruby G, Kneebone A, Pavlakis N, Samra JS, Clarke S. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre. ASCO GI Cancers Symposium; 19-21 January 2017; San Francisco.	Review
2017	32	Iveson T, Kerr R, Saunders M, Hollander NH, Taberero J, Haydon A, Glimelius B, Harkin A, Scudder C, K. B, Waterston A, Medley LC, Wilson C, Ellis R, Essapen S, Dhadda A, Harrison M, Falk S, Abdel- Raouf S, Paul J. Updated results of the SCOT study: an international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. ESMO; 8-12 September 2017; Madrid.	Review
2017	33	Iveson T, Kerr R, Saunders MP, Hollander NH, Taberero J, Haydon AM, Glimelius B, Harkin A, Scudder C, Boyd K, Waterston AM, Medley LC, Wilson C, Ellis R, Essapen S, Dhadda AD, Harrison M, Falk S, Raouf S, Paul J. Final DFS results of the SCOT study: an international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. ASCO Annual Meeting; 2-6 June 2017; Chicago.	SCOT
2017	34	Khasraw M, Hofman MS, Chantrill L, Pavlakis N, GebSKI V, Gill AJ, Markman B, Yip S, Gibbs E, Karapetis C, Wong SF, Ransom DT, Michael M, Wilson K, Simes J, Lipton L. AGITG NABNEC: a randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas. ESMO; 8-12 September 2017; Madrid.	NABNEC
2017	35	Mooi J, Wirapati P, Asher R, Lee C, Savas P, Price T, Tejpar S, Mariadason J, Tebbutt N. Consensus molecular subtypes as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: retrospective analysis of the MAX clinical trial. ESMO; 8-12 September 2017; Madrid	MAX
2017	36	Shapiro JD, Thavaneswaran S, Underhill C, Robledo KP, Karapetis CS, Day FL, Nott LM, M. J, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel G, Waring PM, Tejpar S, Simes J, GebSKI V, Desai J, Segelov E. Results of the quad wild type arm of the AGITG ICECREAM study: a randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA. ASCO Annual Meeting; 2-6 June 2017; Chicago.	ICECREAM
2017	37	Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. ASCO Annual Meeting; 2-6 June 2017; Chicago.	SCOT

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2017	38	Sjoquist KM, Pavlakis N, Martin AJ, Tsobanis E, Yip S, Bang YJ, Alcindor T, O'Callaghan CJ, Shitara K, Bekaii-Saab TS, Grothey A, Chen LT, Simes J, Zalberg R, Goldstein D. Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer—an international study organized by the Australasian Gastrointestinal Trials Group. ASCO Annual Meeting; 2–6 June 2017; Chicago.	INTEGRATE II
2017	39	Vasista A, Martin A, Pavlakis N, Sjoquist K, Snow S, Jonker D, Chua YJ, Epstein R, Bonaventura A, Khasraw M, Varma SC, Singhal N, Ransom D, Aubin F, Burkes RL, Lim H, Lemay F, Begbie S, Stockler M, Kiely B. Accuracy and prognostic significance of oncologists estimates and scenarios for survival time in a randomised phase 2 trial of regorafenib in advanced gastric cancer. ESMO; 8–12 September 2017; Madrid.	INTEGRATE
2017	40	Clinical Trials in Rectal Cancer - What Have We Learned About Laparoscopic Rectal Cancer Surgery? The Z6051, the ALaCaRT, the COREAN and the COLOR II Trials American Society of Colon & Rectal Surgeons Annual Scientific Meeting & Tripartite Meeting, 10-14 June 2017; Seattle.	A La Cart
2016	41	Barbour A, O'Rourke N, Chan H, Chua YJ, Kench J, Hicks RJ, Samra JS, Pavlakis N, Haghghi KS, Yip S, Donoghoe M, Friend C, Burge Me, Fawcett J, Harris M, Aghmesheh M, Joubert WL, GebSKI V, Simes J, Goldstein D. Initial survival outcomes for the AGITG GAP study: a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma. ASCO Annual Meeting; 3–7 June 2016; Chicago.	GAP
2016	42	The Trials of Rectal Cancer (ALaCaRT) American Society of Colon & Rectal Surgeons Annual Scientific Meeting 2016 Los Angeles, USA 30 April – 4 May 2016.	A La Cart
2016	43	Barbour A, Walpole E, Mai GT, Chan H, Barnes E, Watson D, Ackland S, Wills V, Martin J, Burge M, Karapetis C, Shannon J, Nott L, GebSKI V, Wilson K, Thomas J, Lampe G, Zalberg J, Simes J, Smithers M. An AGITG trial: a randomised phase II study of pre-operative cisplatin, fluorouracil and docetaxel ± radiotherapy based on poor early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma. European Society for Medical Oncology 41st Congress; 7–11 October 2016; Copenhagen.	DOCTOR
2016	44	Diakos CI, Tu D, GebSKI V, Yip S, Wilson K, Karapetis C, O'Callaghan CJ, Shapiro J, Tebbutt N, Jonker DJ, Sui LL, Wong R, Doyle C, Strickland AH, Price TJ, Simes J, Clarke S. Is the derived neutrophil to lymphocyte ratio an independent prognostic marker in patients with metastatic colorectal cancer? Analysis of the CO.17 and CO.20 studies. ESMO; 7–11 October 2016; Copenhagen.	CO.17 CO.20
2016	45	Diakos CI, Wilson K, Asher R, GebSKI V, Yip D, van Hazel G, Robinson B, Broad A, Price TJ, Simes J, Tebbutt N, Clarke S. Is baseline neutrophil to lymphocyte ratio an independent prognostic biomarker for progression free survival and overall survival in metastatic colorectal cancer? Analysis of the AGITG MAX study. ESMO; 7–11 October 2016; Copenhagen.	MAX
2016	46	Franco J, Shi Q, Meyers JP, Heinemann V, Falcone A, Tebbutt NC, Maughan T, Seymour M, Saltz L, Tournigand C, Diaz-Rubio E, Souglakos I, Chibaudel B, Moen J, De Gramont A, Adams RA, Sargent DJ, Grothey A. Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer patients treated by systemic chemotherapy: findings from 9,265 patients in the ARCAD database. ASCO GI Cancers Symposium; 21–23 January 2016; San Francisco.	ARCAD
2016	47	Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalberg J, Vickers MM, Wei A, Gao Y, Tebbutt N, Markman B, Esaki T, Koski S, Hitron M, Magoski NM, Simes J, Li C, Tu D, O'Callaghan CJ. A randomized phase III study of nab-paclitaxel [BB1608] vs placebo in patients with pretreated advanced colorectal cancer: the CCTG/AGITG CO.23 trial. ESMO; 7–11 October 2016; Copenhagen.	CO.23
2016	48	Segelov E, Zielinski R, Asghari R, Simes J, Yip S, Coote A, Friend C, Aiken C, Kuang JCW, Jeffery M. ASCOLT: Aspirin for Dukes C and high risk Dukes B colorectal cancers. COSA Annual Scientific Meeting; 15–17 November 2016; Gold Coast.	ASCOLT
2016	49	Sud S, O'Callaghan CJ, Jonker C, Karapetis CS, Price TJ, Tebbutt NC, Shapiro JD, Van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension as a predictor of outcome and treatment response to cetuximab: a retrospective analysis of NCIC CTG CO.17. ASCO GI Cancers Symposium; 21–23 January 2016; San Francisco.	CO.17
2016	50	Sud S, O'Callaghan CJ, Karapetis CS, Jonker C, Price TJ, Tebbutt NC, Shapiro J, Van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: a retrospective analysis of NCIC CTG CO.17. ASCO Annual Meeting; 3–7 June 2016; Chicago.	CO.17
2016	51	Warwick AM, Bernardi MP, Davies L, Stevenson ARL. Comparing three modes of rectal dissection for cancer: open vs laparoscopic vs transanal total mesorectal excision. European Society of Coloproctology 11th Congress; 28–30 September 2016; Milan.	A La Cart
2016	52	Yip S, Harvie R, Martin AJ, Sjoquist KM, Tsobanis E, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Strickland A, Zalberg JR, Simes J, Goldstein D, Pavlakis N. Evaluation of circulating VEGF based biomarkers in INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG). ASCO GI Cancers Symposium; 21–23 January 2016; San Francisco.	INTEGRATE
2015	53	Barbour A, O'Rourke N, Chandrasegaram MD, Chua YJ, Kench J, Samra JS, Pavlakis N, Haghghi KS, Yip S, Fawcett J, Donoghoe M, Walker K, Burge ME, Gananadha S, Harris M, Aghmesheh M, Joubert WL, GebSKI V, Simes J, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study. ASCO Annual Meeting; 29 May–2 June 2015; Chicago.	GAP
2015	54	Laparoscopic Rectal Surgery in Australia: The ALaCaRT Study – SCRS MIS Symposium 10th International Society of Laparoscopic Colorectal Surgery Congress 2015 Academia, SGH Campus, Singapore 2-6 November 2015	A La Cart
2015	55	Rectal Cancer: Optimizing Outcomes through Techniques - ALaCaRT American Society of Colon & Rectal Surgeons Annual Scientific Meeting Boston, Massachusetts, 30 May – 3 June 2015	A La Cart
2015	56	Barbour A, O'Rourke N, Samra JS, Haghghi KS, Kench J, Mitchell J, Pavlakis N, Burge ME, Fawcett J, Gananadha S, Harris M, Aghmesheh M, Chua YJ, Joubert WL, Chan MMK, Chandrasegaram MD, Yip S, Simes J, GebSKI V, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study. ASCO GI Cancers Symposium; 15–17 January 2015; San Francisco.	GAP
2015	57	Chan D, Goldstein D, Sjoquist KM, Pavlakis N. Antiangiogenic agents in metastatic oesophago-gastric cancer: a systematic review and meta-analysis. ASCO Annual Meeting; 29 May–2 June 2015; Chicago.	Review
2015	58	Chin V, Nagrial A, Chantrill L, Sjoquist K, O'Connor C, Pajic M, Biankin A, Yip D. Targeted therapies in the treatment of advanced pancreatic adenocarcinoma: a systematic review and meta-analysis of randomized trials. ASCO Annual Meeting; 29 May–2 June 2015; Chicago.	Review

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2015	59	Goldstein D, Fawcett J, Bridgewater J, Choti M, Wilson K, GebSKI V, Aiken C, Eminton Z, Falk S, Stanton L, Primrose J. Safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer: results from AGITG ATTACHE, CRUK EPOC-B and NSABP C-11. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.	ATTACHE
2015	60	Leong T, Smithers BM, Michael M, GebSKI V, Simes J, Boussioutas A, Miller D, Zalberg J, O'Connell R, Swallow C, Darling G, Wong R, Schuhmacher C, Lordick F, Haustermans K. TOPGEAR: A randomized phase II/III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.	TOPGEAR
2015	61	Pavlikis N, Sjoquist K, Tsobanis E, Martin A, Kang Y, Bang Y, O'Callaghan C, Tebbutt N, Rha S, Lee J, Cho J, Lipton L, Burnell M, Alcindor T, Strickland A, Wong M, Kim J, Simes J, Zalberg J, Goldstein D. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG): first results. Gastrointestinal Cancers Symposium; 15–17 Jan 2015; San Francisco.	INTEGRATE
2015	62	Pavlikis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang YK, Bang YJ, O'Callaghan CJ, Tebbutt NC, Rha SY, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, Simes J, Zalberg J, Goldstein D. INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)—final overall and subgroup results. American Society of Clinical Oncology Annual Meeting; 29 May–2 Jun 2015; Chicago.	INTEGRATE
2015	63	Pavlikis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang Y-K, Bang Y- J, O'Callaghan CJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, Simes J, Zalberg JR, Goldstein D. INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group: final overall and subgroup results. ESMO 17th World Congress on Gastrointestinal Cancer; 1–4 Jul 2015; Barcelona.	INTEGRATE
2015	64	Sebastian L, Verghis J, Simes J, Lee C, Sjoquist K, Biankin A, Nagrial A, Johns A, GebSKI V, Grimison P, Pavlikis N, Asghari R, Miller D, Yip S, Thomas D, Chantrill L. Practical lessons from a pilot study of personalized treatment in pancreatic cancer: the IMPaCT study experience. An intergroup trial of the AGITG/NHMRC CTC/APGI/Kinghorn Cancer Centre/Sydney Catalyst. ACTA (Australian Clinical Trials Alliance) Symposium; 7–10 October 2015; Sydney.	IMPACT
2015	65	Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlikis N, Nott L, Underhill C, Khasraw M, Wasan H, Cardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. AGITG ICECREAM study: the Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation: analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Cancer Congress 2015; 25-29 Sep 2015; Vienna.	ICECREAM
2015	66	Sjoquist KM, Bokemeyer C, Renfro LA, Simes J, Tebbutt NC, S.J. C, Adams R, Punt CJA, Cutsem EV, Douillard JY, Hecht R, Heinemann V, Sougklakos I, Diaz-Rubio E, Porschen R, Meyers JP, Gonsalves WI, Sargent DJ, De Gramont A, Zalberg J. Calculators for overall survival and progression-free survival in metastatic colorectal cancer: construction from 19,678 ARCAD patients. ASCO Annual Meeting; 29 May–2 June 2015; Chicago.	ARCAD
2015	67	Sjoquist KM, Renfro LA, Simes J, Tebbutt NC, Clarke SJ, Meyers JP, Gonsalves WI, Adams R, Seymour MT, Saltz L, Schmolli H, Sargent DJ, De Gramont A, Zalberg JR, on behalf of the Fondation Aide et Recherche en Cancérologie Digestive (ARCAD) Group. Nomograms for overall survival and progression-free survival in metastatic colorectal cancer: construction from 19,678 ARCAD patients. ASCO GI Cancers Symposium; 15–17 January 2015; San Francisco.	ARCAD
2015	68	Verghis J, Miller D, Smithers BM, Murray WK, Crain M, Leong T. Conducting quality assurance processes in a multimodality treatment study involving chemoradiotherapy and surgery—measuring data integrity in the TOPGEAR trial. ACTA 2015 International Clinical Trials Symposium; 7–10 October 2015; Sydney.	TOPGEAR
2014	69	Chantrill L, Sjoquist K, Lee C, Nagrial A, Johns A, Chin V, Chang D, Zalberg J, Yip S, Biankin A, Simes J, Miller D, Sebastian L. Individualised molecular pancreatic cancer therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. AGITG Annual Scientific Meeting; 20-22 August 2014; Brisbane.	IMPACT
2014	70	ALaCaRT: Australasian Laparoscopic Cancer of the Rectum Trial International Breaking Trials Symposium, Tripartite Colorectal Meeting 2014 International Convention Centre, Birmingham, England 30 June-3 July 2014	A La Cart
2014	71	A La CaRT: Australasian laparoscopic cancer of the rectum trial. A phase III randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer Tripartite Colorectal Meeting 2014 International Convention Centre, Birmingham, England 30 June-3 July 2014	A La Cart
2014	72	Laparoscopic Rectal Surgery Trial in Australia (ALaCaRT) 34th Annual Meeting & 2014 International Symposium of the Korean Society of Endoscopic & Laparoscopic Surgeons (KSELS) Seoul, Korea 24-25 April 2014	A La Cart
2014	73	Chionh FJM, GebSKI V, Cheuh AC, Al-Obaidi SJ, Weickhardt AJ, Lee C, Williams DS, Murone C., Wilson K, Scott AM, Simes J, Price TJ, Mariadason JM, Tebbutt NC. Single nucleotide polymorphisms in vascular endothelial growth factor family genes as predictive or prognostic biomarkers in patients with metastatic colorectal cancer: analysis of the phase III MAX study. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	MAX
2014	74	Chua YJ, Karapetis CS, GebSKI V, O'Connell R, Begbie S, Nott LM, Cronk MF, Underhill C, Abdi EA, Van Hagen T, Wong N, Hall M, Ferraro DA, Sjoquist KM, Santos C, Mackey JR, Goldstein D. Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) treated patients with metastatic pancreatic cancer: the randomized phase II PAN1 study. ASCO GI Cancers Symposium; 16–18 January 2014; San Francisco.	PAN1
2014	75	Frenel J, Carreira S, Goodall J, Roda-Perez D, Smith A, Mateo J, Ong M, Gasi-Tendefelt D, Yap TA, Attard G, Nava-Rodrigues D, Molife LR, Kaye SB, Banerji U, deBono JS. Serial next generation sequencing of CFDNA to monitor phase I targeted drug administration. ESMO; 26–30 September 2014; Madrid.	Review
2014	76	Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST Connective Tissue Oncology Society; 15–18 Oct 2014; Berlin.	EORTC 62005

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2014	77	Huguet F, Hammel P, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, Spry N, S Paget-Bailly, Bonnetain F, Louvet C. Impact of chemoradiotherapy on local control and time without treatment in patients with locally advanced pancreatic cancer included in the international phase III LAP 07 study. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	LAP07
2014	78	Jonker DJ, Nott LM, Yoshino T, Li C, Gill S, Shapiro JD, Ohtsu A, Zalberg JR, Vickers MM, Simes J, Wei AC, Mittmann N, Magoski NM, Murray Y, Tsobanis E, Tu D, Kerstein D, O'Callaghan CJ. NCIC CTG and AGITG CO.23 trial: a phase III randomized study of BBI608 plus best supportive care versus placebo plus best supportive care in patients with pretreated advanced colorectal carcinoma. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	CO.23
2014	79	Midgley RS, Love S, Tomlinson I, Johnstone E, Scudder C, Pearson SR, Julier P, Domingo E, Church D, Pezzela F, Hu J, Segelov E, Weaver A, Kerr DJ. Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine ± bevacizumab in the adjuvant setting of stage II/III colorectal cancer. ESMO; 26–30 September 2014; Madrid.	QUASAR 2
2014	80	Nagrial A, Chin VT, Sjoquist K, Chantrill LA, Yip D. Survival benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma: a systematic review of the literature. ASCO GI Cancers Symposium; 16–18 January 2014; San Francisco.	Review
2014	81	Price TJ, Bruhn MA, Lee C, Hardingham JE, Townsend AR, Mann K, Simes J, Weickhardt A, Wrin JW, Wilson K, GebSKI V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab with or without mitomycin C in advanced colorectal cancer. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	MAX
2014	82	Price TJ, Buizen L, Hardingham J, Lee CK, Townsend A, Bruhn M, Simes RJ, Wilson K, GebSKI V, Tebbutt NC. Molecular subgroups from the AGITG MAX trial; right or left primary site of colorectal cancer and outcomes for metastatic colorectal cancer. ESMO; 26–30 September+C83 2014; Madrid.	MAX
2014	83	Price TJ, Townsend AR, Bruhn MA, Lee C, Wrin J, Shivasami A, Arentz G, Tebbutt NC, Cunningham D, Hardingham J. Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer. ASCO GI Cancers Symposium; 16–18 January 2014; San Francisco.	MAX
2014	84	Ricadot S, Hammel P, Chibaudel B, Goldstein D, Spry N, Van Laethem J, Van Houtte P, Glimelius B, Gubanski M, Huguet F. Dummy run in the phase III LAP07 pancreatic cancer trial: First evaluation of quality of radiation therapy planning. American Society for Radiation Oncology 54th Annual Meeting; 28–31 October 2014; San Francisco.	LAP07
2014	85	Roohullah A, Sjoquist K, GebSKI V, Ng W, Chua W., Price T, Tebbutt N, Chantrill L. The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in non-trial patients in two cancer centres. ASCO GI Cancers Symposium; 16–18 January 2014; San Francisco.	MAX
2014	86	Roohullah A, Wong H, Sjoquist K, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, Gibbs P, Chantrill L. Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.	MAX
2014	87	Saad ED, Coart E, Sommeijer DW, Shi Q, Zalberg JR, Burzykowski T, Meyers JP, Hoff PM, Hecht R, Hurwitz H, Tol J, Tebbutt NC, Fuchs CS, Diaz-Robio E, Souglakos J, Falcone A, Kabbinavar FF, Sargent DJ, De Gramont A, Buyse ME, for the ARCAD Group. Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer: analysis of individual patient data from the ARCAD database. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	ARCAD
2014	88	Schmoll H, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne J, Janssens JF, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FW, Hannig CV, Zalberg J, Tebbutt NC, Mauer M, Messina CG, Lutz M, Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine ±oxaliplatin in locally advanced rectal cancer: interim analysis for disease-free survival of PETACC 6. ESMO; 26–30 September 2014; Madrid.	PETACC 6
2014	89	Schmoll HJ, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne JF, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig CV, Zalberg JR, Tebbutt NC, Mauer ME, Messina CGM, Lutz MP, Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. ASCO Annual Meeting; 30 May–3 Jun 2014; Chicago.	PETACC 6
2014	90	Sclafani F, Adams RA, Eng C, Benson AB, Glynne-Jones R, Sebag- Montefiore D, Arnold D, Roy AC, Guren MG, Segelov E, Seymour MT, Bryant A, Peckitt C, Cunningham D, Bridgewater JA, Welch J, O'Dwyer PJ, Dupont E, McConnell A, Rao S. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel in patients with inoperable locally recurrent or metastatic disease. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	InterAACT
2014	91	Shannon J, Goldstein D, Wong N, Chinchen S, Sjoquist K, O'Connell R, Grimison P, McLachlan SA, Tebbutt NC, Lipton L, Vasey P., Cronk MF, Varma SC, Jefford M, Segelov E, Abdi E, Ng S, Karapetis C, GebSKI V, Zalberg J. A multicentre, phase II, open-label, single- arm trial of panitumumab, cisplatin and gemcitabine in biliary tract cancer: primary results of the AGITG TACTIC study. ESMO; 26–30 September 2014; Madrid.	TACTIC
2014	92	Sommeijer DW, Shi Q, Saad ED, Coart E, Buyse ME, Burzykowski T, Meyers JP, Maughan T, Adams RA, Seymour MT, Saltz L, Goldberg RM, Douillard JY, Schmoll HJ, Punt CJA, Tournigand C, Chibaudel B, De Gramont A, Sargent DJ, Zalberg JR, Group For the ARCAD. Early predictors of prolonged overall survival in patients (pts) on first-line chemotherapy for metastatic colorectal cancer: n ARCAD study with individual patient data on 10,962 patients. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	ARCAD
2014	93	Stevenson A, Solomon P, Hewett J, Lumley A, Hague W, GebSKI V, Wilson K, Simes J. A La CaRT: Australasian laparoscopic cancer of the rectum trial. A phase III randomised trial comparing laparoscopic- assisted resection versus open resection for rectal cancer. Tripartite Colorectal Meeting; 30 June–3 July 2014; Birmingham.	A La Cart
2014	94	Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Moore M, André T, Mineur L, Chibaudel B, Louvet C, Bonnetain F. Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial. American Society of Clinical Oncology 50th Annual Meeting; 30 May–3 June 2014; Chicago.	LAP07

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2014	95	Waring PM, Desai J, Rudzki ZB, Wilson K, GebSKI V, Nott LM, Karapetis CS, Khasraw M, Underhill C, Pavlakis N, Chantrill LA, Shapiro JD, Segelov E. Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation) trial in metastatic colorectal cancer. ASCO Annual Meeting; 30 May–3 June 2014; Chicago.	ICECREAM
2013	96	Brulé S, Jonker D, Karapetis C, O'Callaghan C, Moore M, Wong R, Tebbutt N, Underhill C, Yip D, Zalberg J, Tu D, Goodwin R. Location of colon cancer (right-sided versus left-sided) as a predictor of benefit from cetuximab in NCIC CTG CO.17. American Society of Clinical Oncology Annual Meeting; 31 May–4 June 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): 3528.	CO.17
2013	97	Carter H, Zannino D, Simes J, Schofield D, Howard K, Zalberg J, Price T, Tebbutt N. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. 9th World Congress on Health Economics; 7–10 Jul 2013; Sydney.	MAX
2013	98	Casali P, LeCesne A, Valasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Broto J, Gronchi A, Dei Tos A, Marreaud S, Van Der Graaf W, Zalberg J, Litière S, Blay J, EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), Australasian Gastro-Intestinal Trials Group (AGITG). Imatinib failure- free survival in patients with localized gastrointestinal stromal tumors treated with adjuvant imatinib: the EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 10500.	EORTC 62024
2013	99	Casali PG, Zalberg J, Le Cesne A, Reichardt P, Blay JY, Lindner L, Judson I, Fumagalli E, Hogendoorn P, Natukunda A, Marreaud S, Litière S, van Der Graaf WTA. Long-term analysis of a phase III randomized, intergroup, international trial assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.	EORTC 62005
2013	100	Chantrill L, Johns A, Nagrial A, Chin V, Chou A, Pinese M, Mead S, GebSKI V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Asghari R, Harvey S, Pavlakis N, Mukhedkar S, Grimison P, Miller D, Pearson J, Waddell N, Grimmond S, Simes J, Biankin A. The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomised, open label phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer. American Association for Cancer Research-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; 19–23 October 2013; Boston.	IMPACT
2013	101	Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Comparison of chemoradiotherapy and chemotherapy in patients with a locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. ASCO Annual Meeting; 31 May–4 June 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): LBA4003.	LAP07
2013	102	Hohenberger P, Rutkowski P, Bonvalot S, van Coevorden F, Stoeckle E, Olungu C, Ouali M, Casali P, Gronchi A. Analysis of the quality of reporting surgical procedures in patients undergoing resection for primary gastrointestinal stromal tumors: a reporting tool derived from the EORTC–STBSG 62024 trial. ASCO Annual Meeting; 31 May–4 June 2013; Chicago.	EORTC 62024
2013	103	Kumar SS, Kirkpatrick CM, Mann KP, Ray JE, Graham GG, Williams KM, Day RO, Desai J. Imatinib PKPD relationship: Results from an ongoing study. Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Annual Scientific Meeting; 1–4 December 2013; Melbourne.	REGISTER
2013	104	Lee CK, Joensuu H, McArthur G, Montemurro M, Yip D, Goldstein D, Bylina E, Andrzejuk J, Siedlecki JA, Rutkowski P. Development and validation of prognostic nomograms to predict survival outcomes in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first line imatinib therapy. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.	EORTC 62005
2013	105	Neoptolemos J, Greenhalf W, Ghaneh P, Palmer D, Cox T, Garner E, Campbell F, Mackey J, Moore M, Valle J, McDonald A, Tebbutt N, Darvenos C, Glimelius B, Charnley R, Lacaine F, Mayerle J, Rawcliffe L, Bassi C, Buchler M, European Study Group for Pancreatic Cancer. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. ASCO Annual Meeting; 31 May–4 June 2013; Chicago.	ESPAC 3
2013	106	Pavlakis M, Goldstein D, Sjoquist K, Martin A, Tsoibanis E, Yip S, Shannon J, Burge M, Cronk M, Tebbutt N, Strickland A, Lipton L, Price T, Nott L, Harris D, Burnell M, Alcindor T, Bang Y, Kang Y, O'Callaghan C. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer—a study by the Australasian Gastrointestinal Trials Group (AGITG). American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): TPS4157.	INTEGRATE
2013	107	Price T, Hocking C, Broadbridge V, Wrin J, Townsend A, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Hardingham J. Can we accurately report PTEN status in advanced colorectal cancer? European Cancer Congress; 27 Sep–1 Oct 2013; Amsterdam.	MAX
2013	108	Schmoll H, Haustermans K, Price T, Nordlinger B, Hofheinz R, Daisne J, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig C, Zalberg J, Tebbutt N, Mauer M, Messina C, Lutz M, Van Cutsem E, for the EORTC GITCG A, AGITG, EORTC ROG, BGDO, FFCD. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3531.	PETACC 6
2013	109	Segelov E, Wilson K, GebSKI V, Waring P, Tabernero J, Wasan H, Ciardiello F, Desai J, Underhill C, Karapetis C, Khasraw M, Nott L, Joubert W, Pavlakis M, Van Hazel G, Chantrill L, Price T, Jefford M, Haydon A, Shapiro J. ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31(suppl.): TPS3649.	ICECREAM
2013	110	Segelov E, Wilson K, GebSKI V, Waring P, Desai J, Nott L, Karapetis C, Hall M, Wasan H, Shapiro J. ICECREAM: irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. Clinical Oncological Society of Australia 40th Annual Meeting; 12–14 Nov 2013; Adelaide. Asia-Pacific Journal of Clinical Oncology 2013; S3: 155.	ICECREAM

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2013	111	Sommeijer D, Shi Q, Meyers J, Sjoquist K, Hoff P, Seymour M, Cassidy J, Goldberg R, Douillard J, Hecht J, Hurwitz H, Tournigand C, Tebbutt N, Aranda E, Souglakos J, Kabbinar F, Chibaudel B, De Gramont A, Sargent D, Zalberg J, for the ARCAD Group. Prognostic value of early objective tumor response to first-line systemic therapy in metastatic colorectal cancer: individual patient data meta-analysis of randomized trials from the ARCAD database. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3520.	ARCAD
2013	112	Schmoll HJ, Price T, Haustermans K, Nordlinger B, Hofheinz RD, Daisne JF, Janssens J, Schmidt P, Reinel H, van Cutsem E, EORTC GITCG, AIO, AGITG, EORTC ROG, BGDO, FFCD. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: response to the local treatment after chemoradiation and surgery as secondary endpoint. Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie; 18–22 Oct 2013; Vienna.	PETACC 6
2013	113	Tebbutt N, Price T, Sjoquist K, Veillard A, Hall M, Ferraro D, Wong N, Pavlakis M, Strickland A, Varma S, Cooray P, Young R, Underhill C, Shannon J, Ganju V, GebSKI V, Group. AGT. Final results of AGITG ATTAX3 study: randomized phase II study of weekly docetaxel, cisplatin, and fluoropyrimidine with or without panitumumab in advanced esophagogastric cancer. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 4081.	ATTAX 3
2013	114	Vickers M, Tu D, Lee C, Wheatley-Price P, Parulekar W, GBrundage M, Moore M, Au H, O'Callaghan C, Jonker D, Ringash J, Goldstein D. Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): Abstract 4053.	PA3
2013	115	Weickhardt A, Nguyen T, Paskulin D, Le A, Aisner D, Schulte N, Chionh F, Mariadason J, Tebbutt N. ALK and ROS1 gene rearrangements detected in colorectal cancer by fluorescence in situ hybridization. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 3545.	MAX
2012	116	Barbour A, Smithers BM, Burmeister B, Zalberg JR, Spry N, Smith G, Wilson K, Roff K, Yip S, Walpole ET; Australasian Gastro-Intestinal Trials Groups (AGITG). DOCTOR: a randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4145.	DOCTOR
2012	117	Brown C, Hudson M, Yip S, Clarke S, GebSKI V. Incorporating historical control estimates into meta-analyses. Australian Statistical Conference; 9–12 Jul 2012; Adelaide.	DaVINCI
2012	118	Chua Y, Karapetis C, Underhill C, Nott L, Goldstein D, Cronk M, GebSKI V, Wong N, Sjoquist K, Biankin A. PAN1: a randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4137	PAN1
2012	119	Dear R, Barratt A, Evans A, Simes J, Kent D, Newson J, Crossing S, Holliday C, Segelov E, Hruby G, Tattersall M. Identifying and prioritising gaps in colorectal cancer trials research in Australia. Medical Oncology Group of Australia Annual Scientific Meeting; 8–10 Aug 2012 2012; Brisbane.	Review
2012	120	Fawcett J, Sjoquist K, Padbury R, Christophi C, Tebbutt N, Pilgrim C, GebSKI V, Aiken C, Wong N, Goldstein D. ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.	ATTACHE
2012	121	Hurwitz HI, Tebbutt NC, Kabbinar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Taberero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: overall and subgroup analyses of pooled data from randomized controlled trials. ESMO 14th World Congress on Gastrointestinal Cancer; 27–30 Jun 2012; Barcelona. Annals of Oncology 2012; 23(suppl. 4): iv12-13. Abstract 0-0018.	MAX
2012	122	Hurwitz HI, Tebbutt NC, Kabbinar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Taberero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from randomized controlled trials. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.	MAX
2012	123	Jonker D, Karapetis C, O'Callaghan C, Marginean C, Zalberg J, Simes J, Moore M, Tebbutt N, Price T, Daneshmand M, Hanson J, Shapiro J, Pavlakis M, Gibbs P, Van Hazel G, Lee U, Haq R, Virk S, Tu D, Lorimer I, NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. BRAF, PIK3CA, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer: results from NCIC CTG/AGITG CO.17. American Society of Clinical Oncology; 1–5 May Chicago. Abstract 3515.	CO.17
2012	124	Leong T, Smithers M, Michael M, GebSKI V, Boussioutas A, Miller D, Zalberg J, Wong R, Haustermans K. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.	TOPGEAR
2012	125	Midgley RS, Love S, Potter V, Segelov E, Ferry DR, Weaver A, Scudder C, Grumett S, Julier P, Kerr DJ. Capecitabine ± bevacizumab in the adjuvant treatment of colorectal cancer: first and final toxicity results from the international phase III Quasar 2 trial. European Society for Medical Oncology (ESMO) 37th Annual Congress; 28 Sep–2 Oct 2012; Vienna.	QUASAR 2
2012	126	Nagrial A, Biankin A, Chantrill L, Johns A, Chin V, GebSKI V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Pavlakis N, Mukhedkar S, Asghari R, Simes J. The IMPACT trial: Individualised Molecular Pancreatic Cancer Therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. Sydney Cancer Conference; 27–28 Sep 2012; Sydney.	IMPACT
2012	127	Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Primrose J, Walpole E, Mauer M, Gruenberger T, for the EORTC GI Group. CR UK, ALMCAO, AGITG, Nordic Group, and FFCD. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. American Society of Clinical Oncology; 1–5 Jun 2012; Chicago.	EORTC 40983
2012	128	O'Connell M, Lee M, Lopatin M, Yothers G, Clark-Langone K, Millward C, Pail S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV and 5FU/LV+oxaliplatin. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3512 .	CO.7

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2012	129	Price T, Hardingham J, Lee C, Wrin J, Townsend A, Wilson K, Weickhardt A, Simes J, Murone C, Tebbutt N. Analysis of PTEN in patients with advanced colorectal cancer receiving capecitabine alone or in combination with bevacizumab ± mitomycin C in the phase III AGITG MAX trial. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.	MAX
2012	130	Price T, Wilson K, Simes J, Yip D, Tebbutt N, Karapetis C, GebSKI V, Fournier M, Ferry D, Ransom D. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC study—an international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. European Society for Medical Oncology (ESMO) Congress; 28 Sep–2 Oct 2012; Vienna.	ARCTIC
2012	131	Price TJ, Hardingham J, Lee C, Wrin J, Townsend AR, Wilson K, Weickhardt AJ, Simes J, Murone C, Tebbutt NC. PTEN and advanced colorectal cancer: analysis from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab +/- mitomycin C. European Society for Medical Oncology (ESMO) Congress; 28 Sep–2 Oct 2012; Vienna.	MAX
2012	132	Ransom D, Wilson K, Bishnoi S, Simes J, Yip D, Karapetis C, GebSKI V, Gordon S, Fournier M, Ferry D, Abbas H, Midgley R, Price T. Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago.	ARCTIC
2012	133	Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalberg JR, Moore MJ, Strickland AH, Koth R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan SS, Easaw JC, Shannon JA, El-Tahche F, Walters IB, Tu D, O'Callaghan CJ; the NCIC-CTG and the AGITG. Quality of life assessment in patients with K-RAS wild-type chemotherapy refractory metastatic colorectal cancer treated with cetuximab plus brivanib alaninate. ASCO Gastrointestinal Cancers Symposium; 19– 21 Jan 2012; San Francisco.	CO.20
2012	134	Shapiro JD, Siu LL, O'Callaghan CJ, Zalberg JR, Moore MJ, Price TJ, Doyle C, Simes J, Findlay P, Cronk MF, Shaikh A, Joubert WL, Samson B, Bonaventura A, Underhill C, Wyld D, Walters IB, Phillips P, Tu D, Jonker DJ; NCIC CTG AND AGITG. Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: a phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with chemotherapy refractory, k-RAS wild-type metastatic colorectal carcinoma. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3572.	CO.20
2012	135	Siu L, Shapiro J, Jonker D, Karapetis C, Zalberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Tu D, O'Callaghan C, NCIC Clinical Trials Group and AGITG. Final analysis of the phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with metastatic chemotherapy refractory K-RAS wild-type colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract 3504	CO.20
2012	136	Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw WS, Sawyer MB, Jefford M, Magoski NM, Haydon AM, Walters IB, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group and AGITG. Phase III randomized trial of cetuximab plus either brivanib alaninate or placebo in patients with metastatic chemotherapy refractory K-RAS wild-type colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. ASCO Gastrointestinal Cancers Symposium; 19–21 Jan 2012; San Francisco.	CO.20
2012	137	Tebbutt N, Hurwitz H, Kabbinavar F, Giantonio B, Guan Z, Mitchell L, Waterkamp D, Taberero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from randomized controlled trials. ASCO Annual Meeting; 1- 5 Jun 2012; Chicago.	MAX
2011	138	Elimova E, O Callaghan CJ, Tu D, Karapetis CS, Price TJ, Zhu L, Zalberg JR, Simes J, Jonker DJ. Cetuximab related hypersensitivity reactions: An analysis of timing, demographics, and outcomes from the AGITG / NCIC CTG CO.17 trial. ASCO Annual Meeting; 4–8 Jun 2011; Chicago.	CO.17
2011	139	Friedlander M, Schofield P, Wilson K, Jefford M, Zannino D, Stockler M, Tebbutt N, Simes J, Wong N. Hope, optimism and survival in patients diagnosed with metastatic colorectal cancer (an Australasian Gastro-Intestinal Trials Group Study). MASCC/ISOO International Symposium; 23–25 June 2011; Athens.	MAX
2011	140	Goldstein D, Lee C, Tracey E, Cook-Yarborough C, Lord S. Validating innovation: a population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib. ASCO Annual Meeting; 4–8 June 2011; Chicago.	EORTC 62005
2011	141	Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald A, Carter R, Tebbutt NC, Derveniz C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton R, Ghaneh P, Bassi C, Halloran C, Olah A, Rawcliffe CL, Büchler MW, European Study Group for Pancreatic Cancer. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. ASCO Annual Meeting; 4–8 June 2011; Chicago. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract LBA4006.	ESPAC 3
2011	142	O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Tebbutt NC, Trudeau MG, Price TJ, Yip D, Jonker DJ. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. ASCO Annual Meeting; 4–8 June 2011; Chicago.	CO.17
2011	143	Paul J, Briggs A, Harkin A, Haydon AM, Iveson T, Masterson M, Midgley RA, Cassidy J. SCOT: Short Course Oncology Therapy—A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. Journal of Clinical Oncology 2011; 29 (suppl.). Abstract e14145.	SCOT
2011	144	Price T, Zannino D, Wilson K, van Hazel G, Robinson B, Broad A, Ganju V, Ackland S, Simes J, Tebbutt N. Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine, bevacizumab, and mitomycin C; first-line metastatic colorectal cancer. ASCO GI Cancers Symposium; 20– 22 January 2011; San Francisco. Abstract 510.	MAX
2011	145	Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Outcome and dose intensity in the elderly subgroup of the AGITG MAX phase III trial of capecitabine, bevacizumab, and mitomycin C in first-line metastatic colorectal cancer. ASCO Annual Meeting; 4–8 June 2011; Chicago.	MAX
2011	146	Rao A, Sjoquist K, Goldstein D. Second and third line chemotherapy in advanced gastric or gastro-oesophageal cancer: a single institution retrospective case series and review of the literature. COSA Annual Scientific Meeting; 15–17 November 2011; Perth. Asia-Pacific Journal of Clinical Oncology 2011; 7(S4): 119. Abstract 211.	Review

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2011	147	Schofield PE, Stockler MR, Zannino D, Wong N, Ransom D, Moylan EJ, Simes RJ, Price TJ, Tebbutt NC, Jefford M; on behalf of the Australasian Gastrointestinal Trials Group. Do hope, optimism and other psychological factors predict survival in patients with metastatic colorectal cancer? IPOS 13th World Congress of Psycho-Oncology; 16–20 October 2011; Antalya, Turkey.	Review
2011	148	Shapiro J, Siu LL, Zalberg J, Moore M, Ringash J, Mittmann N, Simes J, O'Callaghan CJ, Tu D, Walters I, Magoski N, Smith P, Nomikos D, Zhu L, Savoie M, Virk S, El-Tahche F, Gill R, Price T, Jonker D. A phase III study of cetuximab plus either brivanib alaninate versus placebo in patients with chemotherapy-refractory KRAS wild-type advanced colorectal cancer. The NCIC CTG/AGITG CO.20 trial. ASCO Annual Meeting; 4–8 Jun 2011; Chicago.	CO.20
2011	149	Van Hazel GA, Tu D, Tebbutt C, Jonker DJ, Price TJ, O'Callaghan C, Zalberg JR, Simes J, Yip D, Jefford M, Strickland AH, Burnell MJ, Karapetis CS. Early change in tumor size from waterfall plot analysis and RESIST response as predictor of overall survival in advanced, chemotherapy-refractory colorectal cancer: NCIC CTG/AGITG CO.17 study. ASCO Annual Meeting; 4–8 June 2011; Chicago.	CO.17
2011	150	Vickers MM, Karapetis C, Tu D, Zalberg J, O'Callaghan C, Simes J, Moore M, Zhu L, Jonker DJ. The influence of hypomagnesemia on overall survival in a phase III randomized study of cetuximab plus best supportive care (BSC) versus BSC: NCIC CTG / AGITG CO.17. ASCO Annual Meeting; 4–8 Jun 2011; Chicago.	CO.17
2011	151	Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC; Australasian Gastro-Intestinal Trials Group. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer: analysis of the phase III MAX study. ASCO Annual Meeting; 4–8 Jun 2011; Chicago.	MAX
2010	152	Bishnoi S, Ransom D, Stone C, Gordon S, Simes J, Wilson K, Townsend A, Price T. ARCTIC pilot study: audit of raltitrexed for patients with cardiac toxicity induced by capecitabine/5 fluorouracil. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	ARCTIC
2010	153	Desai J, Goldstein D, McArthur G, Hicks R, Fox S, Kotasek D, Kang YK, Bracken K, GebSKI V, Zalberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. The REGISTER study: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. ASCO Annual Meeting; 4–8 June 2010; Chicago.	Register
2010	154	Desai J, Kang YK, Kotasek D, Robinson B, McArthur GA, Hicks R, Fox SB, GebSKI V, Mann B, Gill RK, Wollin B, Zalberg JR, Goldstein D. REGISTER: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	Register
2010	155	Goldstein D, Spry N, Padbury R, Kneebone A, Barbour A, Biankin A, Harris D, Wong N, Roff K, Shannon J. LAP 07: Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 November 2010; Melbourne.	LAP07
2010	156	Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial: an AGITG multicentre phase II study of fixed-dose-rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. Asian Oncology Summit; 9–11 April 2010; Nusa Dua, Bali.	Gofurtgo
2010	157	Haydon A, Price T, Jefford M, Walpole E, Yip D, Ransom D, Jeffery M, Tebbutt N, Wong N, Wollin B, Segelov E. SCOT: Short Course Oncology Therapy—a study of adjuvant chemotherapy in colorectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	SCOT
2010	158	Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, Joseph DJ, McClure B, McLachlan SA, Mackay J. A randomized trial comparing local recurrence rates between short-course and long-course preoperative radiotherapy for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSA, RACS). ASCO Annual Meeting; 4–8 Jun 2010; Chicago.	TROG 01.04
2010	159	Platell C, GebSKI V, Solomon M, Hewett P, Price T, Quiene S, Wilson K, Tebbutt N. The SUPER study: a randomised phase III multicentre study evaluating the role of palliative surgical resection of the primary tumour in patients with metastatic colorectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	SUPER
2010	160	Price T, Martyn J, Gill R, Hruby G, Gormly K, Harvey J, Ng S, Tebbutt N. PETACC-6: preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 180. Abstract 284.	PETACC 6
2010	161	Price TJ, Hardingham J, Lee C, Weickhardt A, Townsend A, Wrin JW, Shivasami A, Cummins M, Murone C, Tebbutt N. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab ± mitomycin C in advanced colorectal cancer. ESMO Congress; 8–12 October 2010; Milan.	MAX
2010	162	Schofield P, Stockler M, Zannino D, Wong N, Ransom D, Moylan E, Simes RJ, Price TJ, Tebbutt NC, Jefford M; Australasian Gastrointestinal Trials Group (AGITG). Hope, optimism and survival in a randomized trial of first line chemotherapy for patients with metastatic colorectal cancer. ASCO Annual Meeting; 4–8 June 2010; Chicago.	MAX
2010	163	Segelov E, Haydon A, Price T, Jefford M, Walpole E, Yip D, Ransom D, Jeffery M, Tebbutt N, Wong N. SCOT: short course oncology therapy—a study of adjuvant chemotherapy in colorectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 181. Abstract 289.	SCOT
2010	164	Segelov E, Ransom D, Eek R, Begbie S, Price T, Chong G, Jeffery M, Platell C, Solomon M, Farmer C, Wilson K, Roff K, Simes J, Hewett P. QUASAR2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	QUASAR 2
2010	165	Sjoquist K, GebSKI V; on behalf of the Australasian Gastro-Intestinal Trials Group. Updated meta-analysis of survival benefits of neoadjuvant chemotherapy or chemo-radiotherapy followed by surgery in resectable oesophageal carcinoma. AGITG Annual Scientific Meeting; 1–3 September 2010; Adelaide.	IG9401
2010	166	Sjoquist K, Goldstein D, Fawcett J, Padbury R, Christophi C, Tebbutt N, GebSKI V, Wong N, Aiken C. ATTACHE: a trial in the timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 184. Abstract 295.	ATTACHE
2010	167	Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston G, Schlag P, Rougier P, Primrose J, Walpole E, Nordlinger B. Evaluation of carcinoembryonic antigen as a predictive baseline factor for the benefit of perioperative FOLFOX in resectable liver metastasis from colorectal cancer (EORTC study 40983). Gastrointestinal Cancers Symposium 2010.	EORTC 40983

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2010	168	Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston G, Schlag P, Rougier P, Primrose J, Walpole E, Nordlinger B. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). ASCO Annual Meeting; 12-15 May 2010; San Francisco. Journal of Clinical Oncology 2010; 28(15S). Abstract 3544.	EORTC 40983
2010	169	Stevenson A, Hewett P, Lumley J, Clouston A, Simes J, Hague W, GebSKI V, Quiene S, Wilson K, Solomon M. A La CaRT: Australasian Laparoscopic Cancer of the Rectum Trial: a phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	A la CART
2010	170	Stockler M, Zannino D, Wilson K, GebSKI V, Abdi EA, Strickland A, Lowenthal RM, Simes RJ, Price TJ, Tebbutt NC; Australasian Gastro-Intestinal Trials Group (AGITG). Patient-rated outcomes in a randomized trial of first line chemotherapy with capecitabine, bevacizumab, and mitomycin-C for metastatic colorectal cancer: the AGITG MAX trial. ASCO Annual Meeting; 4–8 June 2010; Chicago.	MAX
2010	171	Tebbutt NC, GebSKI VJ, Hall M, Wong N, Veillard AS, Wilcken N, Price TJ. Randomised, phase II study of weekly docetaxel, cisplatin and 5-fluorouracil or capecitabine given with or without panitumumab in advanced oesophago-gastric cancer: the AGITG ATTAX 3 trial. COSA Annual Scientific Meeting; 9–11 November 2010; Melbourne.	ATTAX 3
2009	172	Clarke SJ, Brown C, Simes J, Van Hazel G, Jeffery M, Tebbutt N, Ransom D, Buck M, Boland A, Zalcbberg J; Australasian Gastro- Intestinal Trials Group. AGITG DaVINCI Trial: Randomised phase II trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer. ASCO GI Cancers Symposium; 15–17 January 2009; San Francisco.	DaVINCI
2009	173	Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTO trial: an AGITG multicentre phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3D conformal radiotherapy for the treatment of locally advanced pancreatic cancer. ASCO Annual Meeting; 29 May–2 June 2009; Orlando.	Gofurtgo
2009	174	Jonker D, Karapetis C, Harbison C, O'Callaghan C, Tu D, Simes J, Xu LA, Moore M, Zalcbberg J, Khambata-ford S. High epiregulin gene expression plus KRAS wild-type status predict for cetuximab benefit in the treatment of advanced colorectal cancer: results from NCIC CTG CO.17: a phase III trial of cetuximab vs best supportive care. ASCO Annual Meeting; 29 May–2 June 2009; Orlando.	CO.17
2009	175	Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, Goldstein D. ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. ASCO Annual Meeting; 29 May–2 June 2009; Orlando. Journal of Clinical Oncology 2009; 27: 18s. Abstract LBA4505.	ESPAC 3
2009	176	Powell ED, Asmis T, Jonker D, Tu C, Karapetis C, Jeffery M, O'Callaghan C. Comorbidity and overall survival in cetuximab-treated patients with advanced colorectal cancer—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. ASCO Annual Meeting; 29 May–2 June 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4074.	CO.17
2009	177	Tebbutt NC, GebSKI V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab and mitomycin C in first line metastatic colorectal cancer: final results of the AGITG MAX trial. ECCO 15 and 34th ESMO Multidisciplinary Congress; 20–24 September 2009; Berlin.	MAX
2009	178	Tebbutt NC, GebSKI V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal cancer: final results of the AGITG MAX trial. ASCO Annual Meeting; 29 May–2 June 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 4023.	MAX
2009	179	Van Glabbeke MM, Verweij J, Casali P, Zalcbberg J, Le Cesne A, Reichardt P, Issels R, Judson I, Debiec-Rychter, Blay J. Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor: a study based on the EORTC-ISG- AGITG trial 62005. ASCO Annual Meeting; 29 May–2 June 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 10536.	EORTC 62005
2008	180	Australasian Gastrointestinal Trials Group; Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 243.	ABC
2008	181	Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients' perspectives using baseline data from the MAX study of the Australasian Gastro- Intestinal Trials Group (AGITG). Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 449.	MAX
2008	182	Karapetis C, Khambata-Ford S, Jonker D, O'Callaghan C, Tu D, Vachan B, Simes J, Langer C, Moore M, Zalcbberg J. K-ras mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer — results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. ESMO; 12–16 September 2008; Stockholm. Annals of Oncology 2008; 19: viii2. Abstract LBA6.	CO.17
2008	183	Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcbberg J, Simes J, Evans WK, Jonker DJ. A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. ASCO Annual Meeting; 30 May–3 June 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 6528.	CO.17
2008	184	Ngan SY, McLachlan SA, Fisher R, Burmeister B, Joseph D, Hruby G, Ackland S, Ganju V, Mackay J, Solomon M. A comparison of quality of life in patients with rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group, Australasian Gastrointestinal Trials Group, Colorectal Surgical Society of Australia and New Zealand, and Royal Australasian College of Surgeons trial. Royal Australian and New Zealand College of Radiologists 59th Annual Scientific Meeting; 16–19 Oct 2008; Adelaide.	TROG 01.04
2008	185	O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcbberg JR, Trudeau M, Yip D, Vachan B, Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC–CTC CO.17. ASCO Annual Meeting; 30 May–3 June 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4130.	CO.17

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2008	186	Price T, GebSKI V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. International multicentre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: final safety analysis of the AGITG MAX trial. ASCO Annual Meeting; 30 May–3 June 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 4029.	MAX
2008	187	Price TJ, GebSKI V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. AGITG MAX trial—capecitabine, bevacizumab, and mitomycin C in metastatic colorectal cancer: safety analysis of 400 patients in an international multi- centre randomized phase II–III study. ASCO GI Cancers Symposium; 25–27 January 2008; Orlando. Abstract 449.	MAX
2008	188	Price TJ, GebSKI V, van Hazel G, Robinson B, Broad A, Ganju V, Chua Y, Wilson K, Tunney V, Tebbutt N. Safety analysis of an international multi-centre randomised phase II–III study of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer: AGITG MAX trial. 33rd Congress of the European Society for Medical Oncology; 12–16 September 2008; Stockholm. Ann Oncology 2008; 19 (suppl. 8): viii127. Abstract 365P.	MAX
2008	189	Stockler M, Grimison P, Price T, van Hazel G, Wilson K, Tunney V, Tebbutt N. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients' perspectives using baseline data from the MAX study of the Australasian Gastro-Intestinal Trials Group. ASCO Annual Meeting; 30 May–3 June 2008; Chicago.	MAX
2008	190	Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, GebSKI V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. ASCO GI Cancers Symposium; 25–27 January 2008; Orlando. Abstract 87.	ATTAX 2
2008	191	Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, GebSKI V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. ASCO Annual Meeting; 30 May–3 June 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 15554.	ATTAX 2
2008	192	Wilson K, Munro SC, James R, Tebbutt N, Price TJ, Shapiro J, Wong N. Comparison of ethical and regulatory processes in two multicentre, multiregional oncology clinical trials: an Australian perspective. Clinical Research Excellence 08; 7–9 August 2008; Brisbane.	MAX
2007	193	Au H, Karapetis C, Jonker D, O'Callaghan C, Kennecke H, Shapiro J, Tu D, Wierzbicki R, Zalberg J, Moore M. Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. ASCO Annual Meeting; 1–5 June 2007; Chicago.	CO.17
2007	194	Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K; for the Australasian Gastro-Intestinal Trials Group. ABC: an AGITG trial of fixed dose rate gemcitabine and cisplatin for patients with advanced biliary tract cancer. ASCO Annual Meeting; 1–5 June 2007; Chicago.	ABC
2007	195	Grimison PS, Tebbutt N, Price T, van Hazel G, Wilson K, Tunney V, Stockler M. Comparing utilities for advanced colorectal cancer valued from societal and cancer-patients' perspectives using baseline data from the MAX study of the Australasian Gastro- Intestinal Trials Group (AGITG). COSA Annual Scientific Meeting; 14–17 November 2007; Adelaide.	MAX
2007	196	Jonker DJ, Karapetis CS, Moore MJ, Zalberg JR, Tu D, Au H, Berry S, Krahn M, Simes RJ, Tebbutt N, van Hazel G, O'Callaghan CJ. A phase III randomized study of cetuximab (Erbix, C225) and best supportive care versus best supportive care in patients with pretreated metastatic colorectal carcinoma. American Association for Cancer Research Annual Meeting; 14–18 April 2007; Los Angeles.	CO.17
2007	197	Julié C, Lutz MP, Aust D, Kandutsch S, Collette L, Praet M, Gruenberger T, Van Cutsem E, Nordlinger B. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. Gastrointestinal Cancers Symposium; 19–21 January 2007; Orlando. Abstract 241	EORTC 40983
2007	198	Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, Schache D, Joseph D, Ackland S, McClure B. Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04). 14th European Cancer Conference (ECCO); 23–27 September 2007; Barcelona.	TROG 01.04
2007	199	Nordlinger B, Sorbye H, Collette L, Praet M, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Primrose J, Walpole E, Finch- Jones M, Jaeck D, Mirza D, Parks R, Gruenberger T. Survival after peri-operative chemotherapy with Folfex 4 and surgery for resectable colorectal cancer liver metastases. Final results of the EORTC Intergroup randomized phase III study 40983. World Congress on Gastrointestinal Cancer; 28 Jun–1 July 2007; Barcelona.	EORTC 40983
2007	200	Nordlinger B, Sorbye H, Collette L, Glimelius B, Poston G, Schlag P, Rougier P, Bechstein W, Walpole E, Gruenberger T. Final results of the EORTC Intergroup randomized phase III study 40983 (EPOC) evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. ASCO Annual Meeting; 1–5 June 2007; Chicago.	EORTC 40983
2007	201	Romeo S, Van Paassen H, Van Glabbeke M, Comitel P, Oosting J, Nielsen OS, Verweij J, Sciot R, Debiec-Rychter M, Hogendoorn PCW. Pattern of expression of cell cycle/apoptosis regulators reflect location, mutation and progression free survival (PFS) of gastrointestinal stromal tumour (GIST) treated with imatinib from randomized phase III trial 62005 EORTC/STBSG. European Society of Pathology Annual Congress; 8–13 Sep 2007; Istanbul. Virchows.	EORTC 62005
2007	202	Tebbutt NC, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, GebSKI V, Munro S, Cummins M; on behalf of the Australasian GI Trials Group. ATTAX: randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer: final results of an AGITG trial. ASCO Annual Meeting; 1–5 June 2007; Chicago.	ATTAX
2007	203	Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX study: MAXimising a clinical trial. 28th Annual Meeting of the Society for Clinical Trials; 20–23 May 2007; Montreal.	MAX
2007	204	Tunney V, Munro SC, Tebbutt N, Price T, Wilson K. The MAX Study: MAXimising trial outcomes in a multi-centred, multi-regional clinical trial. International Clinical Trials Symposium; 24–26 September 2007; Sydney.	MAX
2007	205	Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J; GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis based on 1640 patients. ASCO Annual Meeting; 1–5 June 2007; Chicago.	EORTC 62024

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2006	206	Gruenberger T, Sorbye H, Debois M, Bethé U, Primrose J, Rougier P, Jaeck D, Finch-Jones M, Van Cutsem E, Nordlinger B, EORTC GI group. Tumor response to preoperative chemotherapy with Folfox-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2006; Chicago. Journal of Clinical Oncology 2007; 24 (18S, Part I): 3500.	EORTC 40983
2006	207	Le Cesne A, Van Glabbeke M, Verweij J, Casali P, Zalberg J, Reichardt P, Issels RD, Judson IR, Blay JY, Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? ASCO Annual Meeting; 2–6 June 2006; Atlanta.	EORTC 62005
2006	208	Tebbutt N, GebSKI V, Strickland A, Gibbs D, Walpole E, Ganju V, Goldstein D, Munro S, Harrod M, Van Hazel G, Australasian Gastro-Intestinal Trials Group. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. ASCO Annual Meeting; 2–6 June 2006; Atlanta.	ATTAX
2006	209	Tunney V, Munro SC, Tebbutt N, Price T, Wilson K, The MAX study: MAXimising a clinical trial. Applied Clinical Trials 13th Annual European Summit; 17–19 October 2006; Amsterdam.	MAX
2005	210	Casali PG, Verweij J, Kotasek D, LeCesne A, Reichardt P, Blay JY, Issels R, Rychter MD, Van Glabbeke M, Judson I, Imatinib mesylate in advanced gastrointestinal stromal tumors: survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. EJC Supplements 2005; 3(2): 201–202.	EORTC 62005
2005	211	Nordlinger B, Sorbye H, Debois M, Praet M, Glimelius B, Poston G, Schlag P, Walpole E, Bechstein W, Gruenberger T, Feasibility and risks of pre-operative chemotherapy with FOLFOX 4 and surgery for resectable colorectal cancer liver metastases. Interim results of the EORTC Intergroup randomized phase III study 40983. ASCO Annual Meeting; 2-6 Jun 2005; Atlanta.	EORTC 40983
2004	212	Clarke SJ, Goldstein D, Mitchell P, Michael M, Beale P, Friedlander ML, Zalberg J. Modification of leucovorin dose within the FOLFOX regimen improves tolerability without compromising efficacy: a high dose versus low dose comparison. ASCO Annual Meeting; 5–8 Jun 2004; New Orleans.	Review
2004	213	Zalberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg after progression on 400mg: an international, intergroup study of the EORTC, ISG and AGITG. ASCO Annual Meeting; 5–8 June 2004; New Orleans.	EORTC 62005
2003	214	Burmeister B, Smithers B, GebSKI V, Fitzgerald L, Devitt P, Ackland S, Joseph D, Denham J. Pre-operative chemoradiation for oesophageal cancer: results of the Australasian study IG9401. International Conference on Radiation Research; 17–22 August 2003; Brisbane.	IG9401
2003	215	Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Dickman B, GebSKI V, Somatostatin receptor expression and clinical effects of octreotide in patients with advanced hepatocellular carcinoma. COSA Annual Scientific Meeting; 25–28 November 2003; Perth.	AG0001H
2003	216	Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Dickman B, GebSKI V, Somatostatin receptor expression and clinical effects of Sandostatin LAR in patients with advanced hepatocellular carcinoma. American Society of Clinical Oncology; 31 May–3 June 2003; Chicago.	AG0001H
2003	217	Ngan S, Burmeister B, Fisher R, Joseph D, Solomon M, Schache D, Mackay J, Ackland S, Goldstein D, McClure B, McLachlan S, Dhillon H, Thompson P, A randomised trial of preoperative radiotherapy for stage T3 adenocarcinoma of the rectum (TROG 01.04): a progress report. International Conference on Radiation Research (ICRR); 17- 22 August 2003; Brisbane.	TROG 01.04
2003	218	Padbury R, Goldstein D, Knight E, Dhillon H, Tebbutt N, Yip S, Simes J. Continuation of an adjuvant therapy trial in the light of new evidence: revised design of the European Study Group for Pancreatic Cancer 3 trial (ESPAC-3). COSA Annual Scientific Meeting; 25–28 November 2003; Perth.	ESPAC 3
2003	219	Smithers B, Burmeister B, Fitzgerald L, GebSKI V, Denham J, Devitt P, Ackland S, Joseph D, Millar J, North J, Walpole E, Gotley D. A randomized controlled trial of surgery alone compared with chemoradiation and surgery: a focus on the surgical outcomes. 56th Annual Cancer Symposium of the Society of Surgical Oncology; 5–9 March 2003; Los Angeles.	IG9401
2003	220	Van Glabbeke M, Verweij J, Casali P, Zalberg J, Le Cesne A, Reichardt P, Blay J, Schlemmer M, Donato Di Paola E, Judson I, Prognostic factors of toxicity and efficacy in patients with gastro- intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG. ASCO Annual Meeting; 31 May–3 June 2003; Chicago.	EORTC 62005
2003	221	Verweij J, Casali P, Zalberg J, Le Cesne A, Reichardt P, Blay J, Issels R, Van Glabbeke M, Donato Di Paola E, Judson I, Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors: Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. ASCO Annual Meeting; 31 May–3 June 2003; Chicago.	EORTC 62005
2003	222	Zalberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Issels R, Van Glabbeke M, Donato di Paola E, Judson I, Dhillon H, Kotasek D, Findlay M, Goldstein D, Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors: interim results of a randomized phase II trial from EORTC-STBSG, ISG & AGITG. COSA Annual Scientific Meeting; 25–28 November 2003; Perth.	EORTC 62005
2002	223	Burmeister B, Smithers B, Fitzgerald L, GebSKI V, Devitt P, Ackland S, Joseph D, Millar J, North J, Walpole E, Denham J, A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. ASCO Annual Meeting; 18–21 May 2002; Orlando.	TROG 94.01
2002	224	Casali PG, Verweij J, Zalberg J, Le Cesne A, Reichardt P, Ray- Coquard I, Wendtner C, Judson I, Di Paola ED, Van Glabbeke M, Bertulli R, Dhillon H, Nielsen OS. Imatinib (Glivec) 400 vs 800 mg daily in patients with gastrointestinal stromal tumors: a randomized phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group (ISG), and the Australasian Gastro-Intestinal Trials Group (AGITG). A toxicity report. ASCO Annual Meeting; 18–21 May 2002; Orlando.	
2002	225	Cullingford G, Findlay M, Storey D, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, GebSKI V, Dhillon H, A phase II feasibility study of preoperative and postoperative chemotherapy (epirubicin, cisplatin and 4FU) in patients with advanced but operable gastric cancer. ASCO Annual Scientific Meeting; 18–21 May 2002; Orlando.	
2002	226	Gray B, Van Hazel G, Anderson J, Price D, Moroz P, Bower G, Blackwell A, GebSKI V, Randomised phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone on advanced colorectal hepatic metastases. ASCO Annual Scientific Meeting; 18–21 May 2002; Orlando.	
2001	227	Ackland S, Moore M, Jones M, Tu D, Simes R, Yuen J, Sargeant A, Dhillon H, Goldberg R, Abdi E, Shepherd L A, Meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. ASCO Annual Meeting; 12–15 May 2001; San Francisco.	Review

YEAR	NO.	CONFERENCE PRESENTATION	TRIAL
2001	228	Ackland SP, Moore M, Jones M, Tu D, Simes RJ, Yuen J, Sargeant A, Dhillon H, Goldberg R, Abdi E, Shepherd LA. Meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. COSA Annual Scientific Meeting; 28-30 November 2001; Brisbane.	Review
2001	229	Findlay M, Ackland S, GebSKI V, Yuen J, Boyer M, Walpole E, Wilcken N, Zalcbberg J, for the Australasian Gastro-Intestinal Trials Group. Phase II study of irinotecan, leucovorin and 5-fluorouracil in advanced gastric cancer. COSA Annual Scientific Meeting; 28-30 November 2001; Brisbane.	
2001	230	Findlay M, Ackland S, GebSKI V, Yuen J, Boyer M, Walpole E, Wilcken N, Zalcbberg J, Australasian Gastrointestinal Trials Group (AGITG). Phase II study of irinotecan, leucovorin and 5-fluorouracil in advanced gastric cancer. ASCO Annual Meeting; 12-15 May 2001; San Francisco.	
2001	231	Marks P, Dhillon H, Simes J, for the Australasian Gastro-Intestinal Trials Group and NHMRC Clinical Trials Centre. Screening logs for improving recruitment to the NSABP C-07 trial. COSA Annual Scientific Meeting; 28-30 November 2001; Brisbane.	C.07
2001	232	Walpole E, McCall J, Fawcett J, Zalcbberg J, Schroeder J, Dhillon H, for the Australasian Gastro-Intestinal Trials Group. Randomised study of perioperative chemotherapy with infusional fluorouracil/leucovorin and oxaliplatin for liver metastases of colorectal cancer. COSA Annual Scientific Meeting; 28-30 November 2001; Brisbane.	EORTC 40983
2000	233	Storey D, Australian Management Committee. MAGIC-MRC randomised trial of pre- and post-operative chemotherapy for operable gastric cancer: Insights from the Australasian Gastro- Intestinal Trials Group feasibility study (AG9601). COSA Annual Scientific Meeting; 28 November-1 December 2000; Adelaide.	MAGIC
1999	234	Burmeister B, Fitzgerald L, GebSKI V, Stockler M, The Australian randomised oesophageal cancer trial IG 9401: a report on the second analysis. Asia Pacific Cancer Conference; 12-15 December 1999; Chennai.	IG9401
1999	235	Fitzgerald L, Stockler M, GebSKI V, Burmeister B, How do you feel? Baseline quality of life in oesophageal cancer. COSA Annual Scientific Meeting; 24-26 November 1999; Melbourne.	IG9401
1999	236	Fitzpatrick S, Katris P, Dhillon H, Ramsden M, Bell R, Sheinen H, Stockler M, Young A, Cooperative/clinical oncology groups in four states. COSA Annual Scientific Meeting; 25-27 November 1999; Sydney.	Review
1998	237	Yuen J, Lundie-Jenkins H, Ackland S, Solomon M, Goldstein D, Simes J, Asymptomatic metastatic colorectal cancer cohort study: use of a register to assess recruitment and applicability of a randomised trial. COSA Annual Scientific Meeting; 25-27 November 1998; Sydney.	Review
1994	238	Zalcbberg J, Siderov J, Simes J, The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. COSA Annual Scientific Meeting; 27-29 November 1994; Adelaide.	
1992	239	Simes J, The NHMRC Clinical Trials Centre and its role in AGITG studies. COSA Annual Scientific Meeting; 25-27 November 1992; Melbourne.	Review